vs
Ingevity Corp（NGVT）与Tarsus Pharmaceuticals, Inc.（TARS）财务数据对比。点击上方公司名可切换其他公司
Ingevity Corp的季度营收约是Tarsus Pharmaceuticals, Inc.的1.2倍（$185.4M vs $151.7M），Tarsus Pharmaceuticals, Inc.净利率更高（-5.5% vs -45.6%，领先40.1%），Tarsus Pharmaceuticals, Inc.同比增速更快（128.4% vs 36.7%），Ingevity Corp自由现金流更多（$73.5M vs $13.0M），过去两年Tarsus Pharmaceuticals, Inc.的营收复合增速更高（134.4% vs -26.2%）
Ingevity Corp是一家全球特种化学品与先进材料生产商，主营高性能碳材料、路面养护解决方案及特种化工产品，服务汽车排放控制、工业净化、道路基建、农业投入品等核心市场，业务覆盖北美、欧洲及亚太地区。
Tarsus Pharmaceuticals是一家处于后期临床阶段的生物制药公司，专注于眼科、皮肤科等专科领域创新疗法的研发和商业化，主打产品针对蠕形螨睑缘炎、玫瑰痤疮等未被充分诊断的常见病症，核心市场为美国。
NGVT vs TARS — 直观对比
营收规模更大
NGVT
是对方的1.2倍
$151.7M
营收增速更快
TARS
高出91.7%
36.7%
净利率更高
TARS
高出40.1%
-45.6%
自由现金流更多
NGVT
多$60.5M
$13.0M
两年增速更快
TARS
近两年复合增速
-26.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $185.4M | $151.7M |
| 净利润 | $-84.6M | $-8.4M |
| 毛利率 | 41.2% | — |
| 营业利润率 | -47.7% | -5.3% |
| 净利率 | -45.6% | -5.5% |
| 营收同比 | 36.7% | 128.4% |
| 净利润同比 | -609.6% | 63.8% |
| 每股收益（稀释后） | $-2.33 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NGVTTARS
| Q4 25 | $185.4M | $151.7M | ||
| Q3 25 | $333.1M | $118.7M | ||
| Q2 25 | $365.1M | $102.7M | ||
| Q1 25 | $284.0M | $78.3M | ||
| Q4 24 | $135.6M | $66.4M | ||
| Q3 24 | $333.8M | $48.1M | ||
| Q2 24 | $390.6M | $40.8M | ||
| Q1 24 | $340.1M | $27.6M |
净利润NGVTTARS
| Q4 25 | $-84.6M | $-8.4M | ||
| Q3 25 | $43.5M | $-12.6M | ||
| Q2 25 | $-146.5M | $-20.3M | ||
| Q1 25 | $20.5M | $-25.1M | ||
| Q4 24 | $16.6M | $-23.1M | ||
| Q3 24 | $-107.2M | $-23.4M | ||
| Q2 24 | $-283.7M | $-33.3M | ||
| Q1 24 | $-56.0M | $-35.7M |
毛利率NGVTTARS
| Q4 25 | 41.2% | — | ||
| Q3 25 | 40.2% | — | ||
| Q2 25 | 37.8% | — | ||
| Q1 25 | 39.9% | — | ||
| Q4 24 | 81.3% | — | ||
| Q3 24 | 39.4% | — | ||
| Q2 24 | 31.5% | — | ||
| Q1 24 | 29.3% | — |
营业利润率NGVTTARS
| Q4 25 | -47.7% | -5.3% | ||
| Q3 25 | 18.7% | -12.2% | ||
| Q2 25 | -39.1% | -21.6% | ||
| Q1 25 | 9.4% | -33.5% | ||
| Q4 24 | — | -36.8% | ||
| Q3 24 | 33.0% | -52.3% | ||
| Q2 24 | 25.9% | -81.6% | ||
| Q1 24 | 22.6% | -136.5% |
净利率NGVTTARS
| Q4 25 | -45.6% | -5.5% | ||
| Q3 25 | 13.1% | -10.6% | ||
| Q2 25 | -40.1% | -19.8% | ||
| Q1 25 | 7.2% | -32.1% | ||
| Q4 24 | 12.2% | -34.8% | ||
| Q3 24 | -32.1% | -48.7% | ||
| Q2 24 | -72.6% | -81.6% | ||
| Q1 24 | -16.5% | -129.4% |
每股收益（稀释后）NGVTTARS
| Q4 25 | $-2.33 | $-0.17 | ||
| Q3 25 | $1.18 | $-0.30 | ||
| Q2 25 | $-4.02 | $-0.48 | ||
| Q1 25 | $0.56 | $-0.64 | ||
| Q4 24 | $0.44 | $-0.57 | ||
| Q3 24 | $-2.94 | $-0.61 | ||
| Q2 24 | $-7.81 | $-0.88 | ||
| Q1 24 | $-1.54 | $-1.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $78.1M | $417.3M |
| 总债务越低越好 | $1.2B | $72.4M |
| 股东权益账面价值 | $29.7M | $343.4M |
| 总资产 | $1.7B | $562.2M |
| 负债/权益比越低杠杆越低 | 39.10× | 0.21× |
8季度趋势，按日历期对齐
现金及短期投资NGVTTARS
| Q4 25 | $78.1M | $417.3M | ||
| Q3 25 | $83.4M | $401.8M | ||
| Q2 25 | $76.9M | $381.1M | ||
| Q1 25 | $71.5M | $407.9M | ||
| Q4 24 | $68.0M | $291.4M | ||
| Q3 24 | $135.5M | $317.0M | ||
| Q2 24 | $107.4M | $323.6M | ||
| Q1 24 | $88.5M | $298.5M |
总债务NGVTTARS
| Q4 25 | $1.2B | $72.4M | ||
| Q3 25 | $1.2B | $72.3M | ||
| Q2 25 | $1.2B | $72.1M | ||
| Q1 25 | $1.3B | $72.0M | ||
| Q4 24 | $1.3B | $71.8M | ||
| Q3 24 | $1.4B | $71.7M | ||
| Q2 24 | $1.4B | $71.6M | ||
| Q1 24 | $1.4B | $29.9M |
股东权益NGVTTARS
| Q4 25 | $29.7M | $343.4M | ||
| Q3 25 | $138.1M | $335.1M | ||
| Q2 25 | $120.7M | $332.6M | ||
| Q1 25 | $234.6M | $342.5M | ||
| Q4 24 | $195.2M | $224.5M | ||
| Q3 24 | $214.5M | $237.5M | ||
| Q2 24 | $284.8M | $252.2M | ||
| Q1 24 | $568.2M | $275.2M |
总资产NGVTTARS
| Q4 25 | $1.7B | $562.2M | ||
| Q3 25 | $1.8B | $534.6M | ||
| Q2 25 | $1.9B | $495.0M | ||
| Q1 25 | $2.1B | $500.8M | ||
| Q4 24 | $2.0B | $377.0M | ||
| Q3 24 | $2.2B | $376.3M | ||
| Q2 24 | $2.3B | $376.8M | ||
| Q1 24 | $2.6B | $349.3M |
负债/权益比NGVTTARS
| Q4 25 | 39.10× | 0.21× | ||
| Q3 25 | 8.39× | 0.22× | ||
| Q2 25 | 10.24× | 0.22× | ||
| Q1 25 | 5.68× | 0.21× | ||
| Q4 24 | 6.86× | 0.32× | ||
| Q3 24 | 6.52× | 0.30× | ||
| Q2 24 | 4.92× | 0.28× | ||
| Q1 24 | 2.48× | 0.11× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $97.1M | $19.3M |
| 自由现金流经营现金流 - 资本支出 | $73.5M | $13.0M |
| 自由现金流率自由现金流/营收 | 39.6% | 8.6% |
| 资本支出强度资本支出/营收 | 12.7% | 4.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $273.5M | $-22.3M |
8季度趋势，按日历期对齐
经营现金流NGVTTARS
| Q4 25 | $97.1M | $19.3M | ||
| Q3 25 | $129.7M | $18.3M | ||
| Q2 25 | $79.0M | $-29.4M | ||
| Q1 25 | $25.4M | $-20.7M | ||
| Q4 24 | $64.5M | $-22.2M | ||
| Q3 24 | $46.5M | $-8.7M | ||
| Q2 24 | $29.7M | $-14.4M | ||
| Q1 24 | $-12.1M | $-37.8M |
自由现金流NGVTTARS
| Q4 25 | $73.5M | $13.0M | ||
| Q3 25 | $117.8M | $16.3M | ||
| Q2 25 | $66.8M | $-30.4M | ||
| Q1 25 | $15.4M | $-21.2M | ||
| Q4 24 | $39.6M | $-22.3M | ||
| Q3 24 | $28.5M | $-8.9M | ||
| Q2 24 | $11.6M | $-15.4M | ||
| Q1 24 | $-28.7M | $-38.0M |
自由现金流率NGVTTARS
| Q4 25 | 39.6% | 8.6% | ||
| Q3 25 | 35.4% | 13.8% | ||
| Q2 25 | 18.3% | -29.6% | ||
| Q1 25 | 5.4% | -27.1% | ||
| Q4 24 | 29.2% | -33.5% | ||
| Q3 24 | 8.5% | -18.6% | ||
| Q2 24 | 3.0% | -37.8% | ||
| Q1 24 | -8.4% | -137.5% |
资本支出强度NGVTTARS
| Q4 25 | 12.7% | 4.2% | ||
| Q3 25 | 3.6% | 1.6% | ||
| Q2 25 | 3.3% | 1.0% | ||
| Q1 25 | 3.5% | 0.8% | ||
| Q4 24 | 18.4% | 0.1% | ||
| Q3 24 | 5.4% | 0.6% | ||
| Q2 24 | 4.6% | 2.5% | ||
| Q1 24 | 4.9% | 0.6% |
现金转化率NGVTTARS
| Q4 25 | — | — | ||
| Q3 25 | 2.98× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.24× | — | ||
| Q4 24 | 3.89× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NGVT
| Performance Materials | $151.2M | 82% |
| Advanced Polymer Technologies Segment | $36.5M | 20% |
TARS
暂无分部数据
